CytomX Therapeutics (FRA:6C1) E10: €-1.23 (As of Mar. 2026)


FRA:6C1 CytomX Therapeutics Inc FRA:6C1
36 GF Score
Price €2.91
GF Value €0.22
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics E10?

CytomX Therapeutics FRA:6C1 +2.83% 36 E10 is €-1.23 as of Mar. 2026. GuruFocus rates FRA:6C1 with a GF Score™ of 36/100 and a GF Value™ of €0.22 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

CytomX Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.086. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.23 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-30), CytomX Therapeutics's current stock price is €2.909. CytomX Therapeutics's E10 for the quarter that ended in Mar. 2026 was €-1.23. CytomX Therapeutics's Shiller PE Ratio of today is .


CytomX Therapeutics  (FRA:6C1) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


CytomX Therapeutics E10 Related Terms


CytomX Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics E10 Chart

CytomX Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.62 -1.28

CytomX Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.43 0.00 -1.36 -1.28 -1.23

FRA:6C1 vs ALLO, XOMA, OCS: E10 Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Shiller PE Ratio falls into.


FRA:6C1
36GF Score
CytomX Therapeutics Inc FRA:6C1
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytomX Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.086/330.2130*330.2130
=-0.086

Current CPI (Mar. 2026) = 330.2130.

CytomX Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -0.347 241.018 -0.475
201609 -0.356 241.428 -0.487
201612 -0.370 241.432 -0.506
201703 -0.215 243.801 -0.291
201706 -0.614 244.955 -0.828
201709 -0.235 246.819 -0.314
201712 0.025 246.524 0.033
201803 -0.324 249.554 -0.429
201806 -0.300 251.989 -0.393
201809 -0.454 252.439 -0.594
201812 -0.650 251.233 -0.854
201903 -0.274 254.202 -0.356
201906 -0.566 256.143 -0.730
201909 -0.472 256.759 -0.607
201912 -1.314 256.974 -1.688
202003 0.235 258.115 0.301
202006 -0.302 257.797 -0.387
202009 -0.272 260.280 -0.345
202012 -0.822 260.474 -1.042
202103 -0.218 264.877 -0.272
202106 -0.249 271.696 -0.303
202109 -0.298 274.310 -0.359
202112 -0.805 278.802 -0.953
202203 -0.445 287.504 -0.511
202206 -0.426 296.311 -0.475
202209 -0.444 296.808 -0.494
202212 -0.123 296.797 -0.137
202303 -0.047 301.836 -0.051
202306 -0.018 305.109 -0.019
202309 0.037 307.789 0.040
202312 0.009 306.746 0.010
202403 0.156 312.332 0.165
202406 -0.074 314.175 -0.078
202409 0.063 315.301 0.066
202412 0.220 315.605 0.230
202503 0.250 319.799 0.258
202506 0.000 322.561 0.000
202509 -0.077 324.800 -0.078
202512 -0.188 324.054 -0.192
202603 -0.086 330.213 -0.086

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.23 mean?
CytomX Therapeutics (FRA:6C1) has a E10 of €-1.23 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors.
Is CytomX Therapeutics' E10 too high?
CytomX Therapeutics' current E10 is €-1.23. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' E10 compare to ALLO and XOMA?
CytomX Therapeutics' E10 of €-1.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors. CytomX Therapeutics's current E10 is €-1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (FRA:6C1) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.22, compared to a current price of €2.91 — trading 1222.3% above its estimated fair value. The current E10 is €-1.23. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For CytomX Therapeutics (FRA:6C1), the current E10 is €-1.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (FRA:6C1) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of €2.91 is trading 1222.3% above its estimated GF Value™ of €0.22. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:6C1:

  • E10: €-1.23
  • GF Value™: €0.22 vs. price of €2.91 (1222.3% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the FRA:6C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytomX Therapeutics Business Description

Other Exchanges CTMX:USA6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for FRA:6C1

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.91
Price
€0.22
GF Value